{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:26:16Z","timestamp":1758702376626,"version":"3.40.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":745,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.vhri.2014.09.002","type":"journal-article","created":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T09:45:50Z","timestamp":1417081550000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective"],"prefix":"10.1016","volume":"5","author":[{"given":"Bruno Salgado","family":"Riveros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Klarmann","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2014.09.002_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/1744666X.3.2.171","article-title":"Update on the epidemiology and systemic treatment of psoriasis","volume":"3","author":"Kurd","year":"2007","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.vhri.2014.09.002_bib2","unstructured":"Soung J, Lebwohl M. Clinical presentation. In: Gordon KB, Ruderman EM, eds., Psoriasis and Psoriatic Arthritis: An Integrated Approach (1st ed.). Speyer, Germany: Springer, 2005."},{"key":"10.1016\/j.vhri.2014.09.002_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3949\/ccjm.79a.11133","article-title":"Psoriasis: Evolving treatment for a complex disease","volume":"79","author":"Villase\u00f1or-Park","year":"2012","journal-title":"Cleve Clin J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.vhri.2014.09.002_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.07919.x","article-title":"S3 - Guidelines on the treatment of psoriasis vulgaris (English version): update","volume":"10","author":"Nast","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.vhri.2014.09.002_bib5","unstructured":"National Institute for Health and Care Excellence. CG153 Psoriasis: full guideline. 2012. Available from: http:\/\/guidance.nice.org.uk\/CG153\/Guidance\/pdf\/English. [Accessed August 10, 2012]."},{"key":"10.1016\/j.vhri.2014.09.002_bib6","unstructured":"Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psor\u00edase. 2012."},{"key":"10.1016\/j.vhri.2014.09.002_bib7","unstructured":"DAE\/SAS\/MS. Consulta P\u00fablica No 09 de 28 de agosto de 2012. Brasilia, DF: Minist\u00e9rio da Sa\u00fade, 2012."},{"key":"10.1016\/j.vhri.2014.09.002_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib9","unstructured":"SIGN. Diagnosis and management of psoriasis and psoriatic arthritis in adults. Scottish Intercollegiate Guidelines Network. Available from: http:\/\/sign.ac.uk\/guidelines\/fulltext\/121\/index.html. [Accessed November 10, 2014]."},{"key":"10.1016\/j.vhri.2014.09.002_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0001-7310(09)71257-8","article-title":"Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents [in Spanish]","volume":"100","author":"Puig","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.vhri.2014.09.002_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2310\/7750.2011.10066","article-title":"Canadian guidelines for the management of plaque psoriasis: overview","volume":"15","author":"Papp","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.vhri.2014.09.002_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"year":"2009","series-title":"Tratamento T\u00f3pico da Psor\u00edase. Consenso Brasileiro de Psor\u00edase","author":"Martins","key":"10.1016\/j.vhri.2014.09.002_bib14"},{"year":"2009","series-title":"Imunobiol\u00f3gicos na Psor\u00edase. Consenso Brasileiro de Psor\u00edase","author":"Azulay-Abulafia","key":"10.1016\/j.vhri.2014.09.002_bib15"},{"key":"10.1016\/j.vhri.2014.09.002_bib16","unstructured":"Minist\u00e9rio da Sa\u00fade. Relat\u00f3rio de Recomenda\u00e7ao da CONITEC: Medicamentos Biol\u00f3gicos para o tratamento da Psor\u00edase moderada a grave em adultos. Brasilia, DF: Minist\u00e9rio da Sa\u00fade, 2012."},{"issue":"Suppl","key":"10.1016\/j.vhri.2014.09.002_bib17","first-page":"s17","article-title":"Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. Cad Saude Publica. Escola Nacional de Sa\u00fade P\u00fablica","volume":"29","author":"Correr","year":"2013","journal-title":"Funda\u00e7\u00e3o Oswaldo Cruz"},{"key":"10.1016\/j.vhri.2014.09.002_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2014.09.002_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib23","first-page":"1","article-title":"Etanercept and efalizumab for the treatment of psoriasis: a systematic review","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2014.09.002_bib24","unstructured":"Brasil. Diretrizes Metodol\u00f3gicas: estudos de avalia\u00e7\u00e3o econ\u00f4mica de tecnologias em sa\u00fade (1st ed.). Bras\u00edlia, DF: Minist\u00e9rio da Sa\u00fade, 2009."},{"key":"10.1016\/j.vhri.2014.09.002_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.09.002_bib26","unstructured":"IBGE. T\u00e1bua da Vida. Rio de Janeiro, RJ, Brazil: Instituto Brasileiro de Geografia e Estat\u00edstica, 2010."},{"key":"10.1016\/j.vhri.2014.09.002_bib27","doi-asserted-by":"crossref","unstructured":"Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health 15:843\u2013850.","DOI":"10.1016\/j.jval.2012.04.012"},{"key":"10.1016\/j.vhri.2014.09.002_bib28","unstructured":"SIGTAP - Sistema de Gerenciamento da Tabela de Procedimentos. Medicamentos e OPM do SUS. Available from: http:\/\/sigtap.datasus.gov.br\/tabela-unificada\/app\/sec\/inicio.jsp. [Accessed August 9, 2012]."},{"key":"10.1016\/j.vhri.2014.09.002_bib29","unstructured":"CMED. Lista de Pre\u00e7os e Medicamentos - Pre\u00e7os F\u00e1brica e Pre\u00e7o M\u00e1ximo ao Consumidor. 2012. Available from: http:\/\/portal.anvisa.gov.br\/wps\/wcm\/connect\/5dd6198044cfe3389465fd60074bb479\/LISTA+CONFORMIDADE_2014-07-21.pdf?MOD=AJPERES. [Accessed November 10, 2004]."},{"key":"10.1016\/j.vhri.2014.09.002_bib30","doi-asserted-by":"crossref","unstructured":"Costa JG, Santos AC, Rodrigues LC, Barreto ML. Tuberculose em Salvador: custos para o sistema de sa\u00fade e para as fam\u00edlias Tuberculosis in Salvador, Brazil: costs to health system and families. Rev Saude Publica 2005;39:1\u20137","DOI":"10.1590\/S0034-89102005000100016"},{"key":"10.1016\/j.vhri.2014.09.002_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1590\/S0066-782X2005000500013","article-title":"Custo da Insufici\u00eancia Card\u00edaca no Sistema \u00danico de Sa\u00fade","volume":"84","author":"Araujo","year":"2005","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.vhri.2014.09.002_bib32","article-title":"Custo da Doen\u00e7a e perfil dos pacientes dos pacientes com psor\u00edase moderada a grave atendidos no Hospital de Cl\u00ednicas da Universidade Federal do Paran\u00e1","author":"Garcia","year":"2013","journal-title":"Curitiba, Brazil: Universidade Federal do Paran\u00e1"},{"key":"10.1016\/j.vhri.2014.09.002_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.vhri.2014.09.002_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/CEOR.S7348","article-title":"A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy","volume":"1","author":"Colombo","year":"2009","journal-title":"Clinicoecon Outcomes Res"},{"issue":"Suppl. 1","key":"10.1016\/j.vhri.2014.09.002_bib35","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1529-8019.2009.01280.x","article-title":"Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system","volume":"23","author":"De Portu","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.vhri.2014.09.002_bib36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1610-0387.2007.06489.x","article-title":"Cost-effectiveness of psoriasis therapy with etanercept in Germany","volume":"5","author":"Heinen-Kammerer","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.vhri.2014.09.002_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10198-010-0293-8","article-title":"Cost-effectiveness of treatment with etanercept for psoriasis in Sweden","volume":"13","author":"Knight","year":"2012","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vhri.2014.09.002_bib38","doi-asserted-by":"crossref","first-page":"A570","DOI":"10.1016\/j.jval.2012.08.2058","article-title":"Modeling the cost-effectiveness of ustekinumab for moderate to severe plaque psoriasis in US","volume":"15","author":"Marcellusi","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.09.002_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jval.2011.01.006","article-title":"Cost utility analysis based on a head-to-head phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective","volume":"14","author":"Pan","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.09.002_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40273-013-0078-x","article-title":"Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States","volume":"31","author":"Villacorta","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.09.002_bib41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2133.2008.08863.x","article-title":"Economic evaluation of etanercept in the management of chronic plaque psoriasis","volume":"160","author":"Lloyd","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1468-3083.2011.04357.x","article-title":"Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis","volume":"26","author":"Ferr\u00e1ndiz","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vhri.2014.09.002_bib43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1684\/ejd.2009.0725","article-title":"Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system","volume":"19","author":"Greiner","year":"2009","journal-title":"Eur J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.vhri.2014.09.002_bib44","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.09.002_bib45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10778.x","article-title":"Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients","volume":"166","author":"Norlin","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib46","doi-asserted-by":"crossref","first-page":"A147","DOI":"10.1016\/S1098-3015(10)72715-7","article-title":"Modeling the cost-effectiveness of ustekinumab for moderate to severe plaque psoriasis in US","volume":"13","author":"Verma","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.09.002_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-013-0030-z","article-title":"Cost effectiveness of biologic therapies for plaque psoriasis","volume":"14","author":"Ahn","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.vhri.2014.09.002_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2012.11210.x","article-title":"Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach","volume":"167","author":"Goodfield","year":"2012","journal-title":"Br J Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.vhri.2014.09.002_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2012.11209.x","article-title":"Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis","volume":"167","author":"Leman","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib50","unstructured":"National Institute for Health and Care Excellence. TA134 Psoriasis - Infliximab: Guidance. London, UK: National Institute for Health and Care Excellence, 2008."},{"key":"10.1016\/j.vhri.2014.09.002_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","article-title":"Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs","volume":"29","author":"Atteno","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-013-0025-6","article-title":"Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents","volume":"27","author":"Gan","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.vhri.2014.09.002_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"Suppl.","key":"10.1016\/j.vhri.2014.09.002_bib54","first-page":"3","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2014.09.002_bib55","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203309106176","article-title":"Drug-induced lupus: an update on its dermatologic aspects","volume":"18","author":"Marzano","year":"2009","journal-title":"Lupus"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109914000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109914000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:26:15Z","timestamp":1747171575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109914000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":55,"alternative-id":["S2212109914000685"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2014.09.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2014.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}